Clearside, Aura enter license agreement for suprachoroidal space microinjector

Clearside Biomedical has entered into a worldwide license agreement with Aura Biosciences for the use of Clearside’s suprachoroidal space microinjector, according to a press release.
Aura will use the SCS microinjector to deliver its proprietary drug candidates into the suprachoroidal space for the treatment of ocular cancers, including choroidal melanoma, the release said.
“Clearside is committed to expanding the global reach of our SCS injection platform, and this collaboration with Aura broadens the use of our technology into the ocular oncology space,” George Lasezkay,

Full Story →